Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma (SUP-R)

Sunitinib and pazopanib are two effective medications from tyrosine kinase inhibitor pharmacologic class for the first-line treatment of metastatic renal cell carcinoma (mRCC). Nevertheless, the adverse side effects during treatment often lead to dose reductions or even treatment discontinuations.
In order to provide the most efficient treatment to mRCC patients, efficacy and safety of these treatments have to be optimized. In the meantime cost-effective treatment strategies should be followed for more efficient use of healthcare resources.
The purpose of this study is (1) to assess the feasibility and potential benefits of sunitinib and pazopanib dose individualization in terms of efficacy and tolerance, and (2) to investigate whether one could be dispensed instead of another to provide flexibility in clinical practice and more efficient use of healthcare resources. TO BE CONT’D

Faculty Supervisor:

France Varin

Student:

Partner:

Université Paul Sabatier

Discipline:

Life Sciences

Sector:

University:

Université de Montréal

Program:

Globalink Research Award